138 related articles for article (PubMed ID: 22579787)
1. Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells.
Juengel E; Dauselt A; Makarević J; Wiesner C; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Cancer Lett; 2012 Nov; 324(1):83-90. PubMed ID: 22579787
[TBL] [Abstract][Full Text] [Related]
2. Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.
Juengel E; Makarević J; Tsaur I; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
PLoS One; 2013; 8(1):e53100. PubMed ID: 23372654
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.
Wei M; Mao S; Lu G; Li L; Lan X; Huang Z; Chen Y; Zhao M; Zhao Y; Xia Q
BMC Cancer; 2018 Apr; 18(1):434. PubMed ID: 29665787
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Life Sci; 2011 Feb; 88(9-10):418-24. PubMed ID: 21192952
[TBL] [Abstract][Full Text] [Related]
5. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
Kanao K; Mikami S; Mizuno R; Shinojima T; Murai M; Oya M
J Urol; 2008 Sep; 180(3):1131-6. PubMed ID: 18639283
[TBL] [Abstract][Full Text] [Related]
6. Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.
Makarević J; Tawanaie N; Juengel E; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
J Cell Mol Med; 2014 Jul; 18(7):1460-6. PubMed ID: 24779401
[TBL] [Abstract][Full Text] [Related]
7. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Koeffler HP; Yokoyama A
Leukemia; 2008 Dec; 22(12):2159-68. PubMed ID: 18784743
[TBL] [Abstract][Full Text] [Related]
8. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
Vallo S; Xi W; Hudak L; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Anticancer Drugs; 2011 Nov; 22(10):1002-9. PubMed ID: 21822119
[TBL] [Abstract][Full Text] [Related]
9. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
10. Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
Juengel E; Engler J; Mickuckyte A; Jones J; Hudak L; Jonas D; Blaheta RA
BJU Int; 2010 Feb; 105(4):549-57. PubMed ID: 19594733
[TBL] [Abstract][Full Text] [Related]
11. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
12. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
[TBL] [Abstract][Full Text] [Related]
13. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
[TBL] [Abstract][Full Text] [Related]
14. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
Gao D; Xia Q; Lv J; Zhang H
Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
16. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
17. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
Wedel S; Hudak L; Seibel JM; Makarević J; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Clin Exp Metastasis; 2011 Jun; 28(5):479-91. PubMed ID: 21452015
[TBL] [Abstract][Full Text] [Related]
18. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Poli R; Bosco O; Mastrocola R; Aragno M; Boccuzzi G
J Endocrinol; 2006 Nov; 191(2):465-72. PubMed ID: 17088416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
